The DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Current applications of nanoparticles in infectious diseases
Open accessAbstract
For decades infections have been treated easily with drugs. However, in the 21st century, they may become lethal again owing to the development of antimicrobial resistance. Pathogens can become resistant by means of different mechanisms, such as increasing the time they spend in the intracellular environment, where drugs are unable to reach therapeutic levels. Moreover, drugs are also subject to certain problems that decrease their efficacy. This requires the use of high doses, and frequent administrations must be implemented, causing adverse side effects or toxicity. The use of nanoparticle systems can help to overcome such problems and increase drug efficacy. Accordingly, there is considerable current interest in their use as antimicrobial agents against different pathogens like bacteria, virus, fungi or parasites, multidrug-resistant strains and biofilms; as targeting vectors towards specific tissues; as vaccines and as theranostic systems. This review begins with an overview of the different types and characteristics of nanoparticles used to deliver drugs to the target, followed by a review of current research and clinical trials addressing the use of nanoparticles within the field of infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–240 of 240
Italia, J. L., Sharp, J., Carter, K. C., Warn, P. A., & Kumar, M. N. V. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025744 · Cited by 60
Chakraborti, S., Mandal, A. K., Sarwar, S., Singh, P., Chakraborty, R., & Chakrabarti, P. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.03.044 · Cited by 59
Rodriguez, B. A., Asmuth, D. M., Matining, R. M., Spritzler, J., Jacobson, J. M., Mailliard, R. B., Li, X.-D., Martínez, A. I., Tenorio, A. R., Lori, F., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182a99590 · Cited by 58
Functionalised nanoparticles complexed with antibiotic efficiently kill MRSA and other bacteria
Wang, L., Chen, Y. P., Miller, K. P., Cash, B. M., Jones, S. R., Glenn, S., Benicewicz, B. C., & Decho, A. W. (2014) · Chemical Communications · doi:10.1039/c4cc04936e · Cited by 58
Gallyamov, M. O., Chaschin, I. S., Khokhlova, M. A., Grigoriev, T. Е., Bakuleva, N. P., Lyutova, I. G., Kondratenko, J. E., Badun, G. A., Chernysheva, M. G., & Khokhlov, A. R. (2014) · Materials Science and Engineering C · doi:10.1016/j.msec.2014.01.017 · Cited by 57
Shaik, N., Pan, G., & Elmquist, W. F. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21372 · Cited by 55
Zhang, X., Jiang, A., Ma, Z., Li, X., Xiong, Y., Dou, J., & Wang, J. (2015) · Molecules · doi:10.3390/molecules20033972 · Cited by 55
Combatting infectious diseases; nanotechnology as a platform for rational vaccine design
van Riet, E., Ainai, A., Suzuki, T., Kersten, G. F. A., & Hasegawa, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.011 · Cited by 53
Cui, Z., Wang, B., Zhong, Z., Sun, Y., Sun, Q., Yang, G., & Bian, L. (2015) · American Journal of Infection Control · doi:10.1016/j.ajic.2015.03.015 · Cited by 51
Durmus, N. G., & Webster, T. J. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201200215 · Cited by 51
Safety and Biocompatibility of Carbohydrate-Functionalized Polyanhydride Nanoparticles
Vela-Ramirez, J. E., Goodman, J. T., Boggiatto, P. M., Roychoudhury, R., Pohl, N. L. B., Hostetter, J. M., Wannemuehler, M. J., & Narasimhan, B. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9699-z · Cited by 51
Agnandji, S. T., Fendel, R., Mestré, M., Janssens, M., Vekemans, J., Held, J., Gnansounou, F., Haertle, S., von Glasenapp, Oyakhirome, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018559 · Cited by 50
Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages
Chono, S., Kaneko, K., Yamamoto, E. M., Togami, K., & Morimoto, K. (2010) · Drug Development and Industrial Pharmacy · doi:10.3109/03639040903099744 · Cited by 49
Modi, J., Joshi, G., & Sawant, K. K. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.666978 · Cited by 49
Nanotoxicity: The Toxicity Research Progress of Metal and Metal- Containing Nanoparticles
Ding, L., Liu, Z., Aggrey, M. O., et al. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955751507150424104334 · Cited by 49
Webster, T. J., Leuba, K., Durmus, & Taylor (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s38256 · Cited by 48
Waters, V. J., & Ratjen, F. A. (2014) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2014.918507 · Cited by 48
Dodiya, S., Chavhan, S., Sawant, K., & Korde, A. G. (2011) · Journal of Microencapsulation · doi:10.3109/02652048.2011.590612 · Cited by 48
Enhanced Anti-HIV Efficacy of Indinavir After Inclusion in CD4-Targeted Lipid Nanoparticles
Endsley, A. N., & Ho, R. J. Y. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182653c1f · Cited by 47
Preparation of Intravenous Stealthy Acyclovir Nanoparticles with Increased Mean Residence Time
Kamel, A. O., Awad, G. A. S., Geneidi, A. S., & Mortada, N. D. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9342-y · Cited by 45
Long‐acting antituberculous therapeutic nanoparticles target macrophage endosomes
Edagwa, B., Guo, D., Puligujja, P., Chen, H., McMillan, J., Liu, X., Gendelman, H. E., & Narayanasamy, P. (2014) · The FASEB Journal · doi:10.1096/fj.14-255786 · Cited by 43
Kumar, G. S. V., Vadakkan, M. V., Annapoorna, Sivakumar, M., & Mundayoor, S. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s47456 · Cited by 42
Nanomedicines for Treatment of Viral Diseases
Mehendale, R., Joshi, M. D., & Patravale, V. B. (2013) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2013005469 · Cited by 41
Malaria vaccine based on self-assembling protein nanoparticles
Burkhard, P., & Lanar, D. E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1096781 · Cited by 40
Sreeharsha, N. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s34312 · Cited by 38
Saikia, N., Rajkhowa, S., & Deka, R. C. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9638-6 · Cited by 36
Eid, M., & Araby, E. (2013) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-013-0357-1 · Cited by 33
Evliyaoğlu, Y., Kobaner, M., Çelebi, H., et al. (2011) · Urological Research · doi:10.1007/s00240-011-0379-5 · Cited by 33
State of the art and future directions in nanomedicine for tuberculosis
Dube, A., Lemmer, Y., Hayeshi, R. K., Balogun, M. O., Labuschagne, P. W., Swai, H., & Kalombo, L. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.846905 · Cited by 30
Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen
Tiwari, S., Verma, S. K., Agrawal, G. P., & Vyas, S. P. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.04.029 · Cited by 25
Nanopharmaceuticals to target antifilarials: a comprehensive review
Ali, M., Afzal, M., Bhattacharya, S. M., Ahmad, F. J., & Dinda, A. K. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.771630 · Cited by 24
Al‐Badriyeh, D., Liew, D., Stewart, K., & Kong, D. C. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp119 · Cited by 21
Malaria Theranostics using Hemozoin-Generated Vapor Nanobubbles
Lukianova‐Hleb, E. Y., & Lapotko, D. O. (2014) · Theranostics · doi:10.7150/thno.9128 · Cited by 19
Intracellular delivery of drugs to macrophages.
Mukhopadhyay, A., & Basu, S. (2003) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/3-540-36488-9_6 · Cited by 18
Pfurtscheller, K., Petnehazy, T., Goessler, W., Bubalo, V., Kamolz, L., & Trop, M. (2014) · Wound Repair and Regeneration · doi:10.1111/wrr.12209 · Cited by 18
Doudi, M., Naghsh, N., & Setorki, M. (2013) · Medical science monitor basic research/Medical science monitor. Basic research · doi:10.12659/msmbr.883835 · Cited by 16
Martínez‐Gutiérrez, F., Guajardo-Pacheco, J. M., Noriega-Treviño, M. E., Thi, E. P., Reiner, N. E., Orrantia, E., Av‐Gay, Y., Ruíz, F., & Bach, H. (2013) · Future Microbiology · doi:10.2217/fmb.13.5 · Cited by 16
Hwang, T., Fang, C.-L., Al‐Suwayeh, S. A., Yang, L.-J., & Fang, J. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2011.03.022 · Cited by 15
Naik, S., Lundberg, J., Kumar, R. N., Sjölin, J., & Jansen, J. P. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.556145 · Cited by 12
Zhao, G., Huang, Y., Li, G., Li, S., Zhou, Y., Lei, Y., Chen, X., Yang, K., Chen, Y., & Yang, K. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.03.01 · Cited by 2
Cited by
Targeting microbial biofilms: current and prospective therapeutic strategies
Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P., & Hall-Stoodley, L. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.99 · Cited by 1,800
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Nano-Strategies to Fight Multidrug Resistant Bacteria—“A Battle of the Titans”
Baptista, P. V., McCusker, M. P., Carvalho, A., Ferreira, D. A., Mohan, N. M., Martins, M., & Fernandes, A. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01441 · Cited by 881
Ali, A., Shah, T., Ullah, R., Zhou, P., Guo, M., Ovais, M., Tan, Z., & Rui, Y. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.629054 · Cited by 650
Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms
Lee, N.-Y., Ko, W.-C., & Hsueh, P.-R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01153 · Cited by 532
Metadata
- Authors
- Zazo, H., Colino, C. I., & Lanao, J. M.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 224
- Pages
- 86-102
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2227867144
- Cited by
- 434
- References
- 240
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.